sponsored byAAAS Golden Fund

EurekAlert!, a service of AAAS
Home About us
Advanced Search
25-Oct-2014 21:07
US Eastern Time

Username:

Password:

Register

Forgot Password?

Press Releases

Breaking News

Science Business

Grants, Awards, Books

Meetings

Multimedia

Science Agencies
on EurekAlert!

US Department of Energy

US National Institutes of Health

US National Science Foundation

Calendar

Submit a Calendar Item

Subscribe/Sponsor

Links & Resources

Portals

RSS Feeds

Accessibility Option On

Options

Portal Home

Glossary

Background Articles

Research Papers

Meetings

Links & Resources

Disease in the Developing World

News Releases

Key: Meeting M      Journal J      Funder F

Showing releases 126-150 out of 899.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>

Public Release: 13-Aug-2014
JAIDS: Journal of Acquired Immune Deficiency Syndromes
With advances in HIV care, survivors face other disease risks
As effective treatments for HIV become more widely available in low-income and middle-income countries, there's an urgent need to assess and manage health risks in the growing number of people living with HIV. An update on non-communicable diseases among HIV-positive populations in low-income and middle-income countries appears as a supplement to in JAIDS: Journal of Acquired Immune Deficiency Syndromes. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health

Public Release: 13-Aug-2014
Cell Host & Microbe
Ebola protein blocks early step in body's counterattack on virus
The newly published study explains for the first time how the production by the virus of a protein called Ebola Viral Protein 24 stops the interferon-based signals from ramping up immune defenses.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Greg Williams
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 13-Aug-2014
Emerging Microbes & Infections
Researchers uncover clues about how the most important TB drug attacks its target
Researchers at the Johns Hopkins Bloomberg School of Public Health say they have discovered a new clue to understanding how the most important medication for tuberculosis (TB) works to attack dormant TB bacteria in order to shorten treatment.
NIH/National Institute of Allergy and Infectious Diseases, Major Project of the Twelfth Five-Year Plan, National Natural Science Foundation of China

Contact: Stephanie Desmon
sdesmon1@jhu.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health

Public Release: 13-Aug-2014
Cell Host & Microbe
Researchers uncover how Ebola virus disables immune response
The Ebola outbreak in West Africa has brought a lot of attention to the deadly virus. According to the World Health Organization, up to 90 percent of those infected with Ebola die from the virus. Now, researchers publishing Aug. 13 in the journal Cell Host & Microbe reveal how Ebola blocks and disables the body's natural immune response. Understanding how Ebola disarms immune defenses will be crucial in the development of new treatments for the disease.

Contact: Mary Beth O'Leary
moleary@cell.com
617-397-2802
Cell Press

Public Release: 13-Aug-2014
New England Journal of Medicine
Estimated 1.65 million global cardiovascular deaths each year linked to high sodium consumption
More than 1.6 million cardiovascular-related deaths per year can be attributed to sodium consumption above the World Health Organization's recommendation of 2.0 grams per day, researchers have found in a new analysis of populations across 187 countries, to be published in the Aug. 14 issue of the New England Journal of Medicine.
Bill and Melinda Gates Foundation

Contact: Jennifer Kritz
jennifer.kritz@tufts.edu
617-636-3707
Tufts University, Health Sciences Campus

Public Release: 13-Aug-2014
Cell Host & Microbe
Gut flora influences HIV immune response
Normal microorganisms in the intestines appear to play a pivotal role in how the HIV virus foils a successful attack from the body's immune system, according to new research from Duke Medicine.
NIH/National Institute of Allergy and Infectious Diseases, NIH/National Cancer Institute

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
Duke University Medical Center

Public Release: 12-Aug-2014
Journal of Epidemiology and Community Health
Immigrants at lower risk of overdose, death from codeine than people born in Canada
Immigrants are at lower risk of an overdose or death after being prescribed codeine than people born in Canada, a new study has found.
Canadian Drug Safety and Effectiveness Research Network, Institute for Clinical Evaluative Sciences

Contact: Leslie Shepherd
shepherdl@smh.ca
416-864-6094
St. Michael's Hospital

Public Release: 12-Aug-2014
NIH awards $20 million grant to Oak Crest Institute of Science
Researchers at the Oak Crest Institute of Science have been awarded a $20 million grant from the National Institutes of Health to systematically develop an intravaginal ring capable of delivering powerful antiretroviral drugs to prevent the spread of sexually transmitted HIV in women. This Program will allow researchers, for the first time, to rigorously test a large group of antiretroviral drugs in a systematic fashion so that they can determine the best-performing candidates in order to advance them rapidly into clinical trials.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Marc Baum
info@oak-crest.org
626-817-0883
Oak Crest Institute of Science

Public Release: 12-Aug-2014
Protecting newborns: Milk protein could save millions from harm
An international effort led by the University of Sydney hopes to protect hundreds of Bangladeshi newborns from a host of severe health problems by assessing the effect of lactoferrin, a natural protein found in breast and cow's milk, in the treatment of iron deficiency anemia in pregnancy.
Bill and Melinda Gates Foundation, US Agency for International Development, Norwegian Government, Grand Challenges Canada, UK Agency for International Development

Contact: Dan Gaffney
daniel.gaffney@sydney.edu.au
61-411-156-015
University of Sydney

Public Release: 12-Aug-2014
XIII International Congress on Parasitology
New drug candidate for Chagas disease tested in patients in Bolivia
The Drugs for Neglected Diseases initiative announced today at the International Congress of Parasitology, the launch of a Phase II drug trial to test fexinidazole, a drug shelved in the 1980s and 'rediscovered' by DNDi nearly a decade ago, for Chagas disease patients. The drug is also being tested in patients in Africa for two other parasitic diseases, sleeping sickness and visceral leishmaniasis.
Drugs for Neglected Diseases initiative

Contact: Betina Moura
bmoura@dndi.org
55-219-812-22798
Drugs for Neglected Diseases Initiative

Public Release: 12-Aug-2014
PLOS Medicine
Heart failure is a substantial health burden in low- and middle-income countries
Heart failure is a major public health burden in many low- and middle-income countries, with substantial variation in the presentation, causes, management, and outcomes of heart failure across different LMICs, according to a study published in this week's PLOS Medicine. The study, led by Kazem Rahimi and colleagues from the George Institute for Global Health, also finds that a large proportion of patients are not receiving pharmacological treatments for heart failure.
National Institute for Health Research, Oxford Biomedical Research Centre Programme, National Institute for Health Research Career Development Fellowship

Contact: Maya Sandler
medicinepress@plos.org
PLOS

Public Release: 11-Aug-2014
GW researcher receives grant to develop genetic tools to study parasitic infections
John Hawdon, Ph.D., associate professor of microbiology, immunology, and tropical medicine at the George Washington University, was recently awarded $430,722 from the National Institutes of Health to develop a model system to study parasitic nematode infection, which will lead to greater understanding of the infective process and the host's immune response to infection.
National Institutes of Health

Contact: Lisa Anderson
lisama2@gwu.edu
202-994-3121
George Washington University

Public Release: 11-Aug-2014
Grand Challenges Canada funds seven new global health innovations in ASEAN countries
Grand Challenges Canada, funded by the Government of Canada, has announced funding of seven projects implemented in Association of Southeast Asian Nations member countries. This funding, totaling $784,000, will support projects that combine scientific, technical, social and business innovation to solve pressing global health challenges.
Grand Challenges Canada

Contact: Lode Roels
lode.roels@grandchallenges.ca
647-328-2021
Terry Collins Assoc

Public Release: 10-Aug-2014
FASEB Journal
'Worm pill' could ease autoimmune disease symptoms
Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus.

Contact: Lucy Handford
media@monash.edu
Monash University

Public Release: 8-Aug-2014
UTMB receives over $6 million to develop treatment for deadly Ebola and Marburg viruses
A University of Texas Medical Branch at Galveston researcher virologist Alex Bukreyev, professor of pathology, has been awarded two National Institutes of Health grants and a Department of Defense grant totaling more than $6 million to develop experimental drugs against both Ebola and Marburg. Each funded study involves collaborations among teams with different areas of expertise led by Christopher Basler, professor of microbiology at the Icahn School of Medicine at Mount Sinai.
National Institutes of Health, US Department of Defense

Contact: Donna Ramirez
donna.ramirez@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston

Public Release: 8-Aug-2014
Diabetes, Obesity and Metabolism
Study shows type 2 diabetics can live longer than people without the disease
Patients treated with a drug widely prescribed for type 2 diabetes can live longer than people without the condition, a large-scale study involving over 180,000 people has shown.
Bristol Myers-Squibb

Contact: Professor Craig Currie
currie@cardiff.ac.uk
07-824-807-836
Cardiff University

Public Release: 5-Aug-2014
PLOS Medicine
A campaign involving Muslim clerics has increased uptake of polio vaccination in Nigeria
A coalition campaign involving imams, Islamic school teachers, traditional rulers, doctors, journalists, and polio survivors is gradually turning the tide against polio vaccine rejection in northern Nigeria, according to experts from Nigeria writing in this week's PLOS Medicine.
National Primary Health Care Development Agency, World Health Organization

Contact: Maya Sandler
medicinepress@plos.org
PLOS

Public Release: 5-Aug-2014
PLOS Medicine
Pregnant women are often given inappropriate treatment for malaria
Not all pregnant women with symptoms of malaria seek care from their formal healthcare system and if they do seek care, they may be given inappropriate treatment because healthcare providers often fail to adhere to the standard (World Health Organization) diagnostic and treatment guidelines, according to a study by UK researchers published in this week's PLOS Medicine.
Bill and Melinda Gates Foundation

Contact: Maya Sandler
medicinepress@plos.org
PLOS

Public Release: 5-Aug-2014
PLOS Medicine
Monthly preventative treatment with a new drug combination reduces malaria in children
Preventative treatment with a monthly dose of a newer antimalarial drug can reduce the risk of malarial infection among young children, according to a study published in this week's PLOS Medicine. The study, conducted by Victor Bigira and colleagues at San Francisco General Hospital and the Makerere University College of Health Sciences in Kampala, Uganda, finds that treating young children with dihydroartemisinin-piperaquine decreased their risk of contracting malaria.
National Institutes of Health

Contact: Maya Sandler
medicinepress@plos.org
PLOS

Public Release: 4-Aug-2014
Researchers want to know how newest IBS drug helps stomach pain
The newest drug for irritable bowel syndrome has the welcome benefit of relieving the excruciating stomach pain affecting about a third of patients, and researchers want to know how.
Forest Laboratories Inc., Ironwood Pharmaceuticals

Contact: Toni Baker
tbaker@gru.edu
706-721-4421
Medical College of Georgia at Georgia Regents University

Public Release: 4-Aug-2014
Journal of the American College of Cardiology
A polypill strategy to improve global secondary cardiovascular prevention
The polypill, a combination pill taken just once a day that includes key medications for secondary prevention of heart disease, may be an effective low-cost strategy to improve adherence to medication recommendations and reduce costs.

Contact: Rachel Cagan
rcagan@acc.org
202-375-6395
American College of Cardiology

Public Release: 4-Aug-2014
Journal of Cell Biology
Key adjustment enables parasite shape-shifting
Crafty parasites undergo dramatic shape changes that enable them to adapt to different living conditions and thrive. Researchers show that these transformations might not be as difficult as they appear.

Contact: Rita Sullivan King
news@rupress.org
212-327-8603
Rockefeller University Press

Public Release: 31-Jul-2014
Elizabeth Glaser Pediatric AIDS Foundation partners with Riders for Health in Malawi
Today the Elizabeth Glaser Pediatric AIDS Foundation and Riders for Health announced a new partnership that will expedite the delivery of laboratory samples and HIV-related test results to health facilities in two districts of the Northern and Central Zones of Malawi.

Contact: Johanna Harvey
jharvey@pedaids.org
202-280-1657
Elizabeth Glaser Pediatric AIDS Foundation

Public Release: 30-Jul-2014
Academic Medicine
Journal supplement details progress in African medical education
In the first substantial publication by participants of the $130 million Medical Education Partnership Initiative, more than 225 authors detailed progress made at African institutions in a 116-page supplement being published today by the journal Academic Medicine. The collection of 32 articles includes case studies of national strategies to increase numbers of doctors and health professionals trained; educational innovations such as e-learning; research capacity development; and partnerships that leverage advances across the MEPI network.
The President's Emergency Plan for AIDS Relief, National Institutes of Health

Contact: Jeff Gray
jeffrey.gray@nih.gov
301-496-2075
NIH/Fogarty International Center

Public Release: 30-Jul-2014
Antimicrobial Agents and Chemotherapy
Dissolvable fabric loaded with medicine might offer faster protection against HIV
University of Washington bioengineers have discovered a potentially faster way to deliver a topical drug that protects women from contracting HIV. Their method spins the drug into silk-like fibers that quickly dissolve when in contact with moisture, releasing higher doses of the drug than possible with other topical materials.
National Institutes of Health

Contact: Michelle Ma
mcma@uw.edu
206-543-2580
University of Washington

Showing releases 126-150 out of 899.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>